Your session is about to expire
← Back to Search
Vitamin
Riboflavin for Psoriasis
Phase 2
Waitlist Available
Led By Johann Gudjonsson, MD
Research Sponsored by University of Michigan
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
18 years of age or older
Good general health
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights
Study Summary
This study is evaluating whether riboflavin is effective for treating psoriasis.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Subjects Achieving 50% or Greater Psoriasis Area and Severity Index (PASI) Reduction
Secondary outcome measures
Difference in Riboflavin Serum Plasma Levels and Flavin-adenine Dinucleotide (FAD)
Subjects Achieving PASI 75, 90, 100 Response
Subjects Achieving Physician Global Assessment (PGA) Score 0/1
+2 moreTrial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Riboflavin then PlaceboExperimental Treatment1 Intervention
Riboflavin (Vitamin B2) 400 mg oral capsule taken once daily for 12 weeks, followed by 4 week washout period before crossover. At crossover, patients will no longer receive Riboflavin but matching placebo capsule for additional 12 weeks.
Group II: Placebo then RiboflavinPlacebo Group1 Intervention
Placebo oral capsule taken once daily for 12 weeks, followed by 4 week washout period before crossover. At crossover, patients will no longer receive placebo but 400 mg Riboflavin (Vitamin B2) capsule for additional 12 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Riboflavin
FDA approved
Find a Location
Who is running the clinical trial?
University of MichiganLead Sponsor
1,785 Previous Clinical Trials
6,364,807 Total Patients Enrolled
6 Trials studying Psoriasis
219 Patients Enrolled for Psoriasis
Johann Gudjonsson, MDPrincipal InvestigatorUniversity of Michigan
2 Previous Clinical Trials
45 Total Patients Enrolled
1 Trials studying Psoriasis
15 Patients Enrolled for Psoriasis
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger